Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
Authors
Keywords
-
Journal
Biomolecules
Volume 9, Issue 4, Pages 142
Publisher
MDPI AG
Online
2019-04-10
DOI
10.3390/biom9040142
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson’s Disease or Schizophrenia
- (2019) Fabio Del Bello et al. ACS Chemical Neuroscience
- Beta2-Adrenoceptor Agonists in Parkinson’s Disease and Other Synucleinopathies
- (2019) Luca Magistrelli et al. Journal of Neuroimmune Pharmacology
- mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
- (2018) Irene Sebastianutto et al. CURRENT OPINION IN PHARMACOLOGY
- zolpidem ameliorates motor impairments in the unilaterally 6-hydroxydopamine-lesioned rat
- (2018) Robert Assini et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias
- (2018) Tanuja Bordia et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- 1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D4 Receptor
- (2018) Fabio Del Bello et al. JOURNAL OF MEDICINAL CHEMISTRY
- Serotonergic targets for the treatment of l-DOPA-induced dyskinesia
- (2018) Kathryn Lanza et al. JOURNAL OF NEURAL TRANSMISSION
- The striatal cholinergic system in l-dopa-induced dyskinesias
- (2018) X. A. Perez et al. JOURNAL OF NEURAL TRANSMISSION
- Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia
- (2018) Santiago Perez-Lloret et al. JOURNAL OF NEURAL TRANSMISSION
- Dopamine receptors: homomeric and heteromeric complexes in l-DOPA-induced dyskinesia
- (2018) Oscar Solís et al. JOURNAL OF NEURAL TRANSMISSION
- Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease
- (2018) Gonzalo S. Nido et al. NEUROBIOLOGY OF AGING
- Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats
- (2018) Adrian Newman-Tancredi et al. NEUROCHEMICAL RESEARCH
- Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders
- (2018) Robert F. Bruns et al. NEUROPHARMACOLOGY
- DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
- (2018) Tom H. Johnston et al. NEUROPHARMACOLOGY
- Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit
- (2018) Sakari Leino et al. NEUROPHARMACOLOGY
- The highly selective 5-HT 2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l -DOPA-treated parkinsonian marmoset
- (2018) Adjia Hamadjida et al. NEUROPHARMACOLOGY
- A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia
- (2018) Melissa M. Conti et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum
- (2018) Sakari Leino et al. NEUROSCIENCE LETTERS
- Stepping reaction time and gait adaptability are significantly impaired in people with Parkinson's disease: Implications for fall risk
- (2018) Maria Joana D. Caetano et al. PARKINSONISM & RELATED DISORDERS
- The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset
- (2018) Adjia Hamadjida et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
- (2018) Stefania Sgroi et al. Frontiers in Neurology
- Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge
- (2018) Jiyue Zheng et al. ACS Chemical Neuroscience
- The delta-opioid receptor and Parkinson’s disease
- (2018) Jin-Zhong Huang et al. CNS Neuroscience & Therapeutics
- Striatal cholinergic interneurons regulates cognitive and affective dysfunction in partially dopamine depleted mice
- (2018) Samira Ztaou et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?
- (2018) Margherita Torti et al. EXPERT OPINION ON PHARMACOTHERAPY
- An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates
- (2018) Delphine Charvin et al. MOVEMENT DISORDERS
- The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
- (2018) Andrew J. Flores et al. NEUROPHARMACOLOGY
- Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease
- (2018) Ruth L. O'Gorman Tuura et al. Frontiers in Neurology
- Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson’s disease
- (2018) Ulderico Freo et al. Journal of Pain Research
- Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson’s Disease
- (2018) Asma Elmabruk et al. ACS Chemical Neuroscience
- Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
- (2018) Alberto J. Espay et al. ANNALS OF NEUROLOGY
- Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model
- (2018) Pei Zhou et al. BRAIN BEHAVIOR AND IMMUNITY
- Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients
- (2018) Nataša Dragašević-Mišković et al. EXPERT OPINION ON PHARMACOTHERAPY
- Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan
- (2018) Makio Takahashi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques
- (2018) Tom H. Johnston et al. MOVEMENT DISORDERS
- Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat
- (2018) Imane Frouni et al. EXPERIMENTAL BRAIN RESEARCH
- PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
- (2018) Fabiana Núñez et al. Frontiers in Pharmacology
- The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice
- (2018) Herbert Y. Meltzer et al. BEHAVIOURAL BRAIN RESEARCH
- Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds
- (2017) Hongjia Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey
- (2017) S. Perez-Lloret et al. EUROPEAN JOURNAL OF NEUROLOGY
- A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease
- (2017) Wai Kin D. Ko et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias
- (2017) Silvia Cerri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dopaminergic modulation of multi-muscle synergies in postural tasks performed by patients with Parkinson’s disease
- (2017) Ali Falaki et al. JOURNAL OF ELECTROMYOGRAPHY AND KINESIOLOGY
- Return of D4 Dopamine Receptor Antagonists in Drug Discovery
- (2017) Craig W. Lindsley et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4
- (2017) Delphine Charvin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease
- (2017) Susan H. Fox et al. MOVEMENT DISORDERS
- Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias
- (2017) Barbara Picconi et al. MOVEMENT DISORDERS
- Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research
- (2017) Nadhir Litim et al. NEUROPHARMACOLOGY
- The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset
- (2017) Adjia Hamadjida et al. PSYCHOPHARMACOLOGY
- Three-dimensional evaluation of postural stability in Parkinson’s disease with mobile technology
- (2017) Sarah J. Ozinga et al. NEUROREHABILITATION
- Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase
- (2017) Adam Kostelnik et al. Biomed Research International
- Body Posture, Postural Stability, and Metabolic Age in Patients with Parkinson’s Disease
- (2017) Jacek Wilczyński et al. Biomed Research International
- The histamine H3 receptor antagonist thioperamide rescues circadian rhythm and memory function in experimental parkinsonism
- (2017) D Masini et al. Translational Psychiatry
- Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study
- (2017) Joachim Brumberg et al. Annals of Clinical and Translational Neurology
- Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets
- (2017) Anne Michel et al. PLoS One
- Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists
- (2016) Wei Xu et al. ACS Chemical Neuroscience
- Emerging targets and new small molecule therapies in Parkinson’s disease treatment
- (2016) Hongjia Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D 4 R) antagonists
- (2016) Jonathan O. Witt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons
- (2016) Polina Kosillo et al. CEREBRAL CORTEX
- Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors
- (2016) Stephen M. Stahl CNS SPECTRUMS
- Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
- (2016) Jie Dong et al. Current Neuropharmacology
- Opicapone: A Review in Parkinson’s Disease
- (2016) Lesley J. Scott DRUGS
- Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
- (2016) Dhanya Vijayakumar et al. DRUGS
- Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia
- (2016) Tanuja Bordia et al. EXPERIMENTAL NEUROLOGY
- Current and experimental treatments of Parkinson disease: A guide for neuroscientists
- (2016) Wolfgang Oertel et al. JOURNAL OF NEUROCHEMISTRY
- Movement Disorders
- (2016) Anthony Julius et al. MEDICAL CLINICS OF NORTH AMERICA
- Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Antidyskinetic effect of A2Aand 5HT1A/1Breceptor ligands in two animal models of Parkinson's disease
- (2016) Annalisa Pinna et al. MOVEMENT DISORDERS
- Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists
- (2016) Irene Sebastianutto et al. NEUROBIOLOGY OF DISEASE
- Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A 13 C NMR study
- (2016) Puneet Bagga et al. NEUROCHEMISTRY INTERNATIONAL
- An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models
- (2016) Wai Kin D. Ko et al. NEUROPHARMACOLOGY
- In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease
- (2016) Sherise L. Simms et al. NEUROPHARMACOLOGY
- The impact of l-dopa on attentional impairments in a rat model of Parkinson’s disease
- (2016) Elizabeth S. Smith et al. NEUROSCIENCE
- Long-term effect of sub-anesthetic ketamine in reducing l -DOPA-induced dyskinesias in a preclinical model
- (2016) Mitchell J. Bartlett et al. NEUROSCIENCE LETTERS
- Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson’s Disease
- (2016) Mariza Bortolanza et al. NEUROTOXICITY RESEARCH
- Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease
- (2016) Nobutaka Hattori et al. PARKINSONISM & RELATED DISORDERS
- Homocysteine Levels in Parkinson’s Disease: Is Entacapone Effective?
- (2016) Bilge Kocer et al. Biomed Research International
- Memantine and reduced time with dyskinesia in Parkinson′s Disease
- (2015) K. Wictorin et al. ACTA NEUROLOGICA SCANDINAVICA
- Contribution of Axial Motor Impairment to Physical Inactivity in Parkinson Disease
- (2015) Mon S. Bryant et al. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
- Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease
- (2015) Lisa F. Potts et al. ANNALS OF NEUROLOGY
- Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats
- (2015) E. Tronci et al. BEHAVIOURAL BRAIN RESEARCH
- L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat
- (2015) Philippe Huot et al. BEHAVIOURAL PHARMACOLOGY
- Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease
- (2015) Maryka Quik et al. BIOCHEMICAL PHARMACOLOGY
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling
- (2015) Oscar Solís et al. CEREBRAL CORTEX
- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- The 5-HT4Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian RatIn Vivo
- (2015) Sylvia Navailles et al. CNS Neuroscience & Therapeutics
- Dopamine D3 Agonists in the Treatment of Parkinson's Disease
- (2015) Banibrata Das et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The D3 dopamine receptor: From structural interactions to function
- (2015) Chiara Fiorentini et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease
- (2015) Xinxin Yang et al. EXPERIMENTAL NEUROLOGY
- NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat
- (2015) H. Iderberg et al. EXPERIMENTAL NEUROLOGY
- Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands
- (2015) Zdzisław Chilmonczyk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
- (2015) Rajeev Kumar et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat
- (2015) Nirmal Bhide et al. JOURNAL OF NEUROCHEMISTRY
- Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulatesl-DOPA-induced rotational behavior in a rodent model of Parkinson's disease
- (2015) Marie-Therese Fuzzati-Armentero et al. JOURNAL OF NEUROCHEMISTRY
- Nizatidine Ameliorates Slow Transit Constipation in Parkinson's Disease
- (2015) Ryuji Sakakibara et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage
- (2015) Danhui Zhang et al. MOVEMENT DISORDERS
- Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease
- (2015) Carolin Curtze et al. MOVEMENT DISORDERS
- Enhanced histamine H2 excitation of striatal cholinergic interneurons in l-DOPA-induced dyskinesia
- (2015) Sean Austin O. Lim et al. NEUROBIOLOGY OF DISEASE
- Effects of Global Postural Reeducation on gait kinematics in parkinsonian patients: a pilot randomized three-dimensional motion analysis study
- (2015) Valeria Agosti et al. NEUROLOGICAL SCIENCES
- Levodopa–carbidopa intrajejunal gel in advanced Parkinson disease with “on” freezing of gait
- (2015) Giovanni Cossu et al. NEUROLOGICAL SCIENCES
- D3dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia
- (2015) Doris E. Payer et al. NEUROLOGY
- M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia
- (2015) Weixing Shen et al. NEURON
- Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia
- (2015) H. Iderberg et al. NEUROPHARMACOLOGY
- Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist
- (2015) Hanna Iderberg et al. NEUROPHARMACOLOGY
- The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque
- (2015) Philippe Huot et al. NEUROPHARMACOLOGY
- Evidence for a role for α6∗ nAChRs in l-dopa-induced dyskinesias using parkinsonian α6∗ nAChR gain-of-function mice
- (2015) T. Bordia et al. NEUROSCIENCE
- The NR2B antagonist, ifenprodil, corrects the l-DOPA-induced deficit of bilateral movement and reduces c-Fos expression in the subthalamic nucleus of hemiparkinsonian rats
- (2015) Masakazu Igarashi et al. NEUROSCIENCE RESEARCH
- Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease
- (2015) Gennaro Pagano et al. PARKINSONISM & RELATED DISORDERS
- Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs
- (2015) Anne Michel et al. PLoS One
- NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients
- (2015) Manuela Mellone et al. Frontiers in Cellular Neuroscience
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism
- (2014) Veronica Francardo et al. BRAIN
- Postural Sway and Effect of Levodopa in Early Parkinson's Disease
- (2014) Anne Beuter et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
- (2014) Eva Schaeffer et al. CNS DRUGS
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice
- (2014) Dalila Mango et al. EXPERIMENTAL NEUROLOGY
- Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease
- (2014) Manuela Pilleri et al. Expert Opinion On Drug Safety
- Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders
- (2014) Shang-Yi A Tsai et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Pharmacological Treatment of Parkinson Disease
- (2014) Barbara S. Connolly et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
- (2014) Marios Politis et al. JOURNAL OF CLINICAL INVESTIGATION
- The Adenosine A2A-Receptor Antagonist Istradefylline Enhances the Motor Response of L-DOPA Without Worsening Dyskinesia in MPTP-Treated Common Marmosets
- (2014) Shin-ichi Uchida et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: A review
- (2014) Marla Rivera-Oliver et al. LIFE SCIENCES
- Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease
- (2014) Wai Kin D. Ko et al. MOVEMENT DISORDERS
- ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease
- (2014) Danhui Zhang et al. MOVEMENT DISORDERS
- Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis
- (2014) Chuan Zhu et al. NEUROLOGICAL RESEARCH
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
- (2014) Christopher Kobylecki et al. PARKINSONISM & RELATED DISORDERS
- AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys
- (2014) Thérèse Di Paolo et al. PARKINSONISM & RELATED DISORDERS
- Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
- (2014) Olivier Rascol et al. PARKINSONISM & RELATED DISORDERS
- Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries
- (2014) Marlene C. Hechtner et al. PARKINSONISM & RELATED DISORDERS
- The NK1 receptor antagonist N-acetyl-l-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model
- (2014) Emma Thornton et al. PARKINSONISM & RELATED DISORDERS
- Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082
- (2014) Jolanta Konieczny et al. Pharmacological Reports
- Role for the nicotinic cholinergic system in movement disorders; therapeutic implications
- (2014) Maryka Quik et al. PHARMACOLOGY & THERAPEUTICS
- Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
- (2014) Thomas J. Moore et al. JAMA Internal Medicine
- Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations
- (2014) Manolo Carta et al. Frontiers in Neurology
- An Amino Acid Residue in the Second Extracellular Loop Determines the Agonist-Dependent Tolerance Property of the Human D3 Dopamine Receptor
- (2013) Sara Gil-Mast et al. ACS Chemical Neuroscience
- Effects of 5-HT1A Receptor Stimulation on D1 Receptor Agonist-Induced Striatonigral Activity and Dyskinesia in Hemiparkinsonian Rats
- (2013) Kristin B. Dupre et al. ACS Chemical Neuroscience
- D-512 and D-440 as Novel Multifunctional Dopamine Agonists: Characterization of Neuroprotection Properties and Evaluation of In Vivo Efficacy in a Parkinson’s Disease Animal Model
- (2013) Soumava Santra et al. ACS Chemical Neuroscience
- Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias: Studies with parkinsonian nicotinic receptor knockout mice
- (2013) Maryka Quik et al. BIOCHEMICAL PHARMACOLOGY
- Is Nicotine Protective Against Parkinsons Disease? An Experimental Analysis
- (2013) Jose-Ruben Garcia-Montes et al. CNS & Neurological Disorders-Drug Targets
- Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience
- (2013) M. Zibetti et al. EUROPEAN JOURNAL OF NEUROLOGY
- Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action
- (2013) Hanna Iderberg et al. EXPERIMENTAL NEUROLOGY
- Functionally Selective Dopamine D2/D3 Receptor Agonists Comprising an Enyne Moiety
- (2013) Christine Hiller et al. JOURNAL OF MEDICINAL CHEMISTRY
- The nicotine-mediated decline inl-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release
- (2013) Tanuja Bordia et al. JOURNAL OF NEUROCHEMISTRY
- Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens
- (2013) Xiomara A. Perez et al. JOURNAL OF NEUROCHEMISTRY
- A phase I single and repeated dose pharmacokinetic study of oral V81444, a selective non-xanthine adenosine A2A receptor antagonist
- (2013) S. Pawsey et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Nizatidine ameliorates gastroparesis in Parkinson's disease: A pilot study
- (2013) Hirokazu Doi et al. MOVEMENT DISORDERS
- Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
- (2013) Stewart A. Factor et al. MOVEMENT DISORDERS
- AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Caffeine consumption and risk of dyskinesia in CALM-PD
- (2013) Anne-Marie A. Wills et al. MOVEMENT DISORDERS
- Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease
- (2013) Maryka Quik et al. MOVEMENT DISORDERS
- Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
- (2013) Erwan Bezard et al. MOVEMENT DISORDERS
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys
- (2013) Nicolas Morin et al. NEUROPHARMACOLOGY
- α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats
- (2013) Maryka Quik et al. NEUROPHARMACOLOGY
- In vitro and in vivo characterization of the agonist-dependent D3 dopamine receptor tolerance property
- (2013) Samantha R. Cote et al. NEUROPHARMACOLOGY
- Rapid Anxiolytic Effects of a 5-HT4 Receptor Agonist Are Mediated by a Neurogenesis-Independent Mechanism
- (2013) Indira Mendez-David et al. NEUROPSYCHOPHARMACOLOGY
- Perampanel in Parkinson Disease Fluctuations
- (2012) Olivier Rascol et al. CLINICAL NEUROPHARMACOLOGY
- Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
- (2012) M. A. Cenci et al. CNS & Neurological Disorders-Drug Targets
- Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
- (2012) J. J. Ferreira et al. EUROPEAN JOURNAL OF NEUROLOGY
- Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats
- (2012) Fabrice Billet et al. EXPERIMENTAL NEUROLOGY
- Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
- (2012) C. Moreau et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Direct and GABA-mediated indirect effects of nicotinic ACh receptor agonists on striatal neurones
- (2012) Ruixi Luo et al. JOURNAL OF PHYSIOLOGY-LONDON
- Alterations in the histaminergic system in Alzheimer's disease: a postmortem study
- (2012) Ling Shan et al. NEUROBIOLOGY OF AGING
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
- (2012) P. A. LeWitt et al. NEUROLOGY
- Caffeine for treatment of Parkinson disease: A randomized controlled trial
- (2012) R. B. Postuma et al. NEUROLOGY
- Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice
- (2012) Maryka Quik et al. NEUROPHARMACOLOGY
- The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease
- (2012) Kari A. Johnson et al. NEUROPHARMACOLOGY
- Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease
- (2012) M. Amalric et al. NEUROPHARMACOLOGY
- Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia
- (2012) Khaled-Ezaheir Bennouar et al. NEUROPHARMACOLOGY
- Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata
- (2011) M Broadstock et al. BRITISH JOURNAL OF PHARMACOLOGY
- Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia
- (2011) Francesco Errico et al. EXPERIMENTAL NEUROLOGY
- Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
- (2011) Kristin B. Dupre et al. EXPERIMENTAL NEUROLOGY
- Highly Potent 5-Aminotetrahydropyrazolopyridines: Enantioselective Dopamine D3Receptor Binding, Functional Selectivity, and Analysis of Receptor−Ligand Interactions
- (2011) Nuska Tschammer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nicotine Reduces L-DOPA-Induced Dyskinesias by Acting at 2* Nicotinic Receptors
- (2011) L. Z. Huang et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease
- (2011) Andrew Lees et al. MOVEMENT DISORDERS
- Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
- (2011) Christopher Kobylecki et al. MOVEMENT DISORDERS
- The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease
- (2011) James B. Koprich et al. MOVEMENT DISORDERS
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
- (2011) Susan H. Fox et al. MOVEMENT DISORDERS
- Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats
- (2011) Luping Z. Huang et al. NEUROPHARMACOLOGY
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
- (2011) Emmanuelle Pourcher et al. PARKINSONISM & RELATED DISORDERS
- Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats
- (2011) Christopher J. Barnum et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
- (2011) Hideyuki Sawada et al. PLoS One
- Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
- (2011) Véronique Sgambato-Faure et al. PROGRESS IN NEUROBIOLOGY
- The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-dopa-induced dyskinesias
- (2011) C. Marin et al. SYNAPSE
- CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist
- (2011) Jianyong Chen et al. ACS Medicinal Chemistry Letters
- Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease
- (2010) Pamela J. McMillan et al. BRAIN RESEARCH
- Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors
- (2010) L Lladó-Pelfort et al. BRITISH JOURNAL OF PHARMACOLOGY
- Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
- (2010) Robert A. Hodgson et al. EXPERIMENTAL NEUROLOGY
- Computational Modeling Toward Understanding Agonist Binding on Dopamine 3
- (2010) Yaxue Zhao et al. Journal of Chemical Information and Modeling
- Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease
- (2010) Christopher Kobylecki et al. JOURNAL OF NEUROCHEMISTRY
- Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease
- (2010) K. J. Black et al. JOURNAL OF NEUROSCIENCE
- Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition
- (2010) V. Paille et al. JOURNAL OF NEUROSCIENCE
- In Vivo Characterization of MMP-2200, a Mixed / Opioid Agonist, in Mice
- (2010) J. J. Lowery et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Nicotinic Receptor-Mediated Reduction in L-DOPA-Induced Dyskinesias May Occur via Desensitization
- (2010) T. Bordia et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Effect of histamine H2receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease
- (2010) Tom H. Johnston et al. MOVEMENT DISORDERS
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
- (2010) Elisabeth Wolf et al. MOVEMENT DISORDERS
- The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
- (2010) Tom H. Johnston et al. MOVEMENT DISORDERS
- Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
- (2010) Karla Eggert et al. MOVEMENT DISORDERS
- A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
- (2010) Daniella Rylander et al. NEUROBIOLOGY OF DISEASE
- Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys
- (2010) Nicolas Morin et al. NEUROPHARMACOLOGY
- MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism
- (2010) Melanie A. Paquette et al. NEUROPHARMACOLOGY
- Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia
- (2010) Emanuela Santini et al. PLoS One
- Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice
- (2010) Y. Ding et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of tolerance in D3 dopamine receptor signaling is accompanied by distinct changes in receptor conformation
- (2009) Ligia Westrich et al. BIOCHEMICAL PHARMACOLOGY
- Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1Areceptor agonist
- (2009) A Newman-Tancredi et al. BRITISH JOURNAL OF PHARMACOLOGY
- Development of (S)-N6-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and Its Analogue as a D3 Receptor Preferring Agonist: Potent in Vivo Activity in Parkinson’s Disease Animal Models
- (2009) Balaram Ghosh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study
- (2009) Giuseppe Meco et al. JOURNAL OF NEURAL TRANSMISSION
- Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression
- (2009) R. A. Hodgson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
- (2009) D. Rylander et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia
- (2009) Karen L. Eskow Jaunarajs et al. NEUROREPORT
- The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
- (2009) Melanie A. Paquette et al. PSYCHOPHARMACOLOGY
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors
- (2008) S. Ferre et al. CURRENT PHARMACEUTICAL DESIGN
- Identification of Dopamine D1–D3Receptor Heteromers
- (2008) Daniel Marcellino et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Continuous and Intermittent Nicotine Treatment Reduces L-3,4-Dihydroxyphenylalanine (L-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease
- (2008) T. Bordia et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization
- (2008) C. Fiorentini et al. MOLECULAR PHARMACOLOGY
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
- Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function
- (2008) Carla Ferrada et al. NEUROPHARMACOLOGY
- A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
- (2008) K VANOVER et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Adenosine in the central nervous system: release mechanisms and extracellular concentrations
- (2003) Serena Latini et al. JOURNAL OF NEUROCHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now